You are here: Industry Insights > Novartis

News List

FDA approves Novartis’ oral multiple sclerosis drug Mayzent pharmaceutical-technology
April 11, 2019
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its relapsing multiple sclerosis (RMS) drug Mayzent (siponimod)...
Novartis continues to ‘reimagine’ itself, as Alcon spin-off completed pharmatimes
April 11, 2019
Novartis has announced the completion of its Alcon eye care spin-off.
Novartis’ Cosentyx lands first-in-class Chinese psoriasis nod fiercepharma
April 10, 2019
Novartis’ psoriasis blockbuster Cosentyx has beaten out rivals from Eli Lilly and Johnson & Johnson as the first interleukin-17A inhibitor approved in China.
Post-Alcon Novartis eyes M&A in ophthalmic digital therapeutics fiercepharma
April 10, 2019
Now that Alcon is officially off on its own, what is Novartis’ remaining eye medicine business looking at next? According to Nikos Tripodis...
Novartis clear to focus on prescription drugs with completion of Alcon spin-off firstwordpharma
April 09, 2019
Novartis announced Tuesday that it completed the spin-off of its Alcon eye care devices business into a standalone ……
Novartis and Amgen dispute over migraine drug reaches court pharmaceutical-technology
April 09, 2019
Novartis and Amgen dispute over migraine drug reaches court
As Amgen seeks to can Aimovig collaboration, Novartis sues to save the deal fiercepharma
April 08, 2019
Novartis and Amgen were the first to tap into a hot market with their CGRP migraine prevention drug Aimovig……
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen……
ICER says price for Biogen's Spinraza, estimated value for Novartis' Zolgensma are too high firstwordpharma
April 04, 2019
The Institute for Clinical and Economic Review (ICER) on Wednesday issued a final report indicating that Biogen and Ionis Pharmaceuticals' spinal muscle atrophy (SMA) therapy Spinraza (nusinersen) is not cost-effective at its current price.
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre worldpharmanews
April 04, 2019
Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page